Ad
ASND - Ascendis Pharma A S Stock Trading
About | Ascendis Pharma A/S (NASDAQ:ASND)
Not available
Quote | Ascendis Pharma A/S (NASDAQ:ASND)
| Last: | $95.50 |
|---|---|
| Change Percent: | 0.68% |
| Open: | $94.41 |
| Close: | $95.50 |
| High: | $96.68 |
| Low: | $93.01 |
| Volume: | 180,510 |
| Last Trade Date Time: | 09/25/2023 03:00:00 am |
News | Ascendis Pharma A/S (NASDAQ:ASND)
-
- The majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit - Trial demonstrated the long-term safety of TransCon hGH in patients treated up to 6 years ...
-
2023-09-15 11:05:45 ET More on Lilly, Ascendis, and Novartis Eli Lilly: A Potential Game Changer For Weight Management And Cardiovascular Health Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge Sandoz to commercialize biosimilar to J&J blockbuster drug ...
Message Board Posts | Ascendis Pharma A/S (NASDAQ:ASND)
| Subject | By | Source | When |
|---|---|---|---|
| Short today at 85.34 | MiamiGent | investorshub | 05/01/2023 8:42:43 PM |
| Ascendis Pharma: FDA Approves Skytrofa to Treat Pediatric | crudeoil24 | investorshub | 08/25/2021 9:19:58 PM |
| ASCENDIS PHARMA A/S is a Danish-based biopharmaceutical company, | crudeoil24 | investorshub | 08/25/2021 9:17:30 PM |
Ad
-
- The majority of children and adolescents treated once weekly with TransCon hGH (lonapegsomatropin) met or exceeded average parental height SDS at time of treatment completion or last visit - Trial demonstrated the long-term safety of TransCon hGH in patients treated up to 6 years ...
-
COPENHAGEN, Denmark, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the launch in Germany of SKYTROFA ® (lonapegsomatropin), its growth hormone approved in the European Union for the once-weekly treatment of children and adolescents ages 3 to 1...
-
- Final European Commission decision expected within 67 days after positive opinion; if approved, first European Union launch planned in Germany in early 2024 COPENHAGEN, Denmark, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Europe...